Reckitt Benckiser To Acquire Adams Respiratory (ARXT) for $60/Share
More News related to ARXT
- Matrix USA Rating Changes 1/09
- Unusual 11 Mid-Day Movers: MBIA, PMI Higher; Celegene Lower on Clinical Results (MBI, PMI, CELG)
- Notable Mergers and Acquisitions of the Day: Blackstone May Bid for Rio Tinto (RTP), Elsai Buys MGI PHARMA (MOGN)
- Pre-Open Movers 12/10: Adams Respiratory, MGI PHARMA Higher on Buyouts; Hemispherx is Lower on License Termination (ARXT, MOGN, HEB)
- Reckitt Benckiser To Acquire Adams Respiratory (ARXT) for $60/Share
Reckitt Benckiser Group plc and Adams Respiratory Therapeutics (Nasdaq: ARXT) entered into a definitive agreement under which Reckitt Benckiser will tender for the acquisition of Adams for $60 per share in cash, representing a total consideration for Adams' fully diluted share capital of approximately $2.3 billion.
The transaction will be financed by Reckitt Benckiser by cash on hand and existing credit facilities.
Shares of Adams Respiratory closed at $43.68 on Friday.
Related Categories
Hot ListMergers and Acquisitions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
